Ines Brückmann

Featured in: Favicon

Articles

Comparing anti-drug antibody signal-to-noise ratios to assess immunogenicity and interchangeability in adalimumab biosimilar studies

Nov 15, 2024 | tandfonline.com | Andrew Blauvelt |Hillel Cohen |Lena Lemke |Ines Brückmann

ABSTRACTBackground To support an interchangeability designation for Sandoz adalimumab biosimilar (GP2017), antidrug antibody (ADA) signal-to-noise (S/N) ratios were assessed in the GP2017 ADACCESS trial to directly assess potential changes in immunogenicity.

Try JournoFinder For Free

Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.